LYCOS RETRIEVER 
Organon: Agreement
built 623 days ago
Under the agreement, Organon is returning all rights and know-how related to Gepirone ER to Fabre-Kramer, including sponsorship of NDA 21-164 for Major Depressive Disorder, which was determined by the FDA in June 2004 as not approvable. Fabre-Kramer is assuming certain obligations of Organon for ongoing pediatric trials. In the event of FDA approval of Gepirone ER, Organon will receive a milestone payment and will ... receive royalties based on future sales of Gepirone ER.
Source:
Under the terms of the agreement, Organon will perform the preclinical and clinical development of the portfolio and will hold worldwide commercialization rights for any resulting products. Uriach receives an upfront payment and will ... receive milestone payments at various stages of development and royalties on future product sales. Uriach also receives an option to commercialize in the Spanish market one of Organon´s late-stage products. Further terms of the agreement were not disclosed.
Source:
With this agreement Organon will benefit from a professionally managed 7*24 hours support organization while at the same time lowering their operational costs. Vincent van Geerestein, senior vice president Global ICT at Organon says: “Maintaining the flexibility, trust and responsiveness to the business demand of Organon forms the basis to the business relationship between Organon and Atos Origin”.
Source:
MORE ABOUT
Agreement